Skip to main content

Advertisement

Table 6 QALY and (percent patient value gains) for triple combination therapy cohorts associated with zeaxanthin use and with no zeaxanthin use

From: Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

Model TTZ vs. control cohort TT vs. control cohort TTZ vs. TT
First-eye model 0.453 (6.7 %) 0.339 (5.0 %) 0.115 (1.6 %)
Second-eye model 0.653 (14.1 %) 0.400 (8.7 %) 0.253 (5.0 %)
Combined-eye model 0.521 (8.2 %) 0.359 (6.0 %) 0.162 (2.5 %)
Combined-eye model p < 0.0001 p < 0.0001 p < 0.0001
  1. TTZ triple therapy with zeaxanthin, TT triple therapy
  2. Combined-eye model = 66 % first-eye model and 34 % second-eye model, Zeaxanthin = Zx